Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Vor Biopharma (VOR – Research Report). The associated price ...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients ...

Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of abstracts that aim to improve treatments for patients with lymphoma and acute leukemias at ...

Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax ...

Copies of the abstracts are now available online on the ASH website ... in patients with R/R mutant nucleophosmin (mNPM1) acute myeloid leukemia (AML). Topline data is expected in the fourth ...

"We are pleased with our operational and clinical execution this quarter and look forward to sharing additional clinical data ...

ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML ...

in relapsed/refractory acute myeloid leukemia (r/r AML) will be presented at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held on December 7 –10 ...

"The data being presented this year at ASH demonstrate Syndax's commitment ... patients with R/R mutant nucleophosmin (mNPM1) acute myeloid leukemia (AML). Topline data is expected in the fourth ...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid ... at the 66th American Society of Hematology ...

Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral ...